The essence of health disorder caused by purine bodies as the substrates

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K11784
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 59040:Nutrition science and health science-related
• Research Institution: Meiji Pharmaceutical University
• Principal Investigator: Kushiyama Akifumi 明治薬科大学, 薬学部, 教授 (30435820)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 尿酸

Outline of Final Research Achievements

The XO vaccine for suppression of plasma XOR activity was designed by Professor Keinori Nakagami of Osaka University Graduate School of Medicine. The system attacked only XOR on cell membranes and in plasma, and actually reduced plasma XOR to a level similar to plasma XOR activity in macrophage XORKO mice. The XOR vaccine-treated mice showed lower fat accumulation in the liver, lower visceral fat weight and brown cell weight, and reduced inflammation compared to control vaccine-treated mice. In other words, the metabolic abnormalities were corrected by the reduction of extracellular XOR levels.

Free Research Field

生活習慣病

Academic Significance and Societal Importance of the Research Achievements

組織特異的XORKOマウスでの検討と比較すると、マクロファージXOR欠損の場合と臨床像としては似通っており、NASHにおける炎症の病態はマクロファージの細胞表面にXORの作用が関与していることが示唆された。本研究成果を発表することにより、ワクチンを用いた生活習慣病治療、血管障害の治療が可能となる端緒となることが期待される。